2026
conference-abstract
OpenAlex
Anthony M. Sun, Sara J. Venters, C. Yau, D. M. Wolf et autres
Abstract Background. Pathologic complete response (pCR) is the absence of residual invasive cancer in the breast and axillary lymph nodes after neoadjuvant therapy. In breast cancer treatment, pCR is a proven surrogate for long-term outcomes. However, accurately predicting pCR at diagnosis remains …
us, nl
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
T. B. V. Bui, D. M. Wolf, CC Yau, R. W. Sayaman et autres
Abstract Introduction: The I-SPY2 neoadjuvant platform trial (NCT01042379) evaluates new therapies in high molecular risk, stage 2-3 breast cancer patients. Between 2010 and 2022, 24 therapies were tested in 2,117 patients. One-third of these patients had HER2-negative tumors with low expression of …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Don Yee, C. Yau, P. Norwood, D. M. Wolf et autres
Abstract Introduction: AC plus a taxane is standard neoadjuvant therapy for high-risk early breast cancer, but AC may be unnecessary for pathologic complete response (pCR) in many patients. I-SPY2 is a phase 2 trial evaluating the use of 12 weeks of paclitaxel …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
D. M. Wolf, H. S. Rugo, R. Nanda, S. Umashankar et autres
Abstract Background Neoadjuvant immunotherapy has become standard of care for triple negative (TN) breast cancer; and I-SPY2 and other trials have shown efficacy of IO in HR+HER2-, especially in immune+ subsets. However, IO agents carry risk of immune-related toxicities, some long-term. Previously …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
M. J. Magbanua, D. M. Wolf, Nayelis A. Manon, Rosalyn W. Sayaman et autres
Abstract Background: ctDNA dynamics are emerging as a promising biomarker for predicting treatment response. In the I-SPY2 trial, early clearance of ctDNA during neoadjuvant therapy (NAT) has been shown to predict treatment response across receptor subtypes (Magbanua et al., Cancer Cell, 2023). …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Tam Binh V. Bui, D. M. Wolf, R. W. Sayaman, C. Yau et autres
Abstract Introduction The I-SPY2 neoadjuvant platform trial (NCT01042379) evaluates new therapies in high molecular risk breast cancer patients. From 2010-2022, 24 therapies were tested in 2117 patients. One-third of these patients had HER2-negative tumors with low expression of immune genes and no …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
W. Li, N. Onishi, John Kornak, C. Yau et autres
Abstract Background: Functional tumor volume (FTV) measured from MRI serves as an imaging biomarker for redirecting treatment in the I-SPY 2 trial. This study aims to validate FTV-based MRI models used to predict favorable response early in treatment. Methods: The study cohort …
us
(code pays fourni par la source)